Psychostimulant Augmentation During Treatment With Selective Serotonin Reuptake Inhibitors in Men With Paraphilias and Paraphilia-Related Disorders: A Case Series
J Clin Psychiatry 2000;61:664-670
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: We describe an open trial of
psychostimulants (primarily methylphenidate sustained release
[SR]) added to selective serotonin reuptake inhibitors (SSRIs;
primarily fluoxetine) during the course of pharmacologic
treatment of men with paraphilias and paraphilia-related
Method: Twenty-six men with paraphilias (N = 14)
or PRDs (N = 12) were assessed for lifetime mood disorders and
attention-deficit/hyperactivity disorder (ADHD) as defined by
DSM-IV. All men were assessed at baseline for total sexual outlet
and average time per day associated with paraphilia/PRD sexual
behaviors. The indications for the addition of a psychostimulant
to a stable dose of SSRI included the retrospective diagnosis of
ADHD with persistent adult symptoms despite pharmacotherapy with
an SSRI (N = 17); residual paraphilia/PRD fantasies, urges, and
activities despite SSRI pharmacotherapy (N = 16); the persistence
or presence of residual depressive symptoms despite SSRI
pharmacotherapy (N = 6); relapse or loss of SSRI efficacy during
the treatment of sexual impulsivity disorders (N = 4); and
treatment of SSRI-induced side effects (N = 4).
Results: SSRI pharmacotherapy (mean ± SD
duration = 8.8 ± 11.1 months) had statistically significant
effects in diminishing paraphilia/PRD-related total sexual outlet
(p < .001) and average time/day spent in paraphilia/PRD sexual
behavior (p < .001). Addition of methylphenidate SR (mean dose
= 40 mg/day; mean ± SD duration = 9.6 ± 8.2 months) was
associated with additional statistically significant effects on
paraphilia/PRD-related total sexual outlet (p = .003) and average
time per day (p = .04) in addition to improvement of putative
residual ADHD and depressive symptoms.
Conclusion: Methylphenidate SR can be cautiously
and effectively combined with SSRI antidepressants to ameliorate
paraphilias and paraphilia-related disorders for the indications